Last reviewed · How we verify
Liposomal bupivacaine plus bupivacaine — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Liposomal bupivacaine plus bupivacaine (Liposomal bupivacaine plus bupivacaine) — Beijing Tiantan Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Liposomal bupivacaine plus bupivacaine TARGET | Liposomal bupivacaine plus bupivacaine | Beijing Tiantan Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Liposomal bupivacaine plus bupivacaine CI watch — RSS
- Liposomal bupivacaine plus bupivacaine CI watch — Atom
- Liposomal bupivacaine plus bupivacaine CI watch — JSON
- Liposomal bupivacaine plus bupivacaine alone — RSS
Cite this brief
Drug Landscape (2026). Liposomal bupivacaine plus bupivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-bupivacaine-plus-bupivacaine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab